Fifth Circuit Vacates CMS Medicare Advantage 2023 RADV

If you work in Medicare Advantage, you already know RADV is not just another sleepy government acronym. It is the acronym that can ruin lunch, stress out actuaries, and make compliance teams stare into the middle distance while whispering, “How many charts are left?” The fight over the CMS Medicare Advantage 2023 RADV rule matters because it sits right at the intersection of risk adjustment, overpayment recovery, documentation standards, and plain old regulatory muscle.

Here is the important truth up front: while this article keeps the requested title for SEO purposes, the underlying legal story is a bit more precise. The vacatur that shook the industry came from a federal district court in Texas, and the case is now tied up in the Fifth Circuit on appeal. That distinction matters, but so does the bigger point: the 2023 RADV framework that CMS wanted to use for extrapolated Medicare Advantage recoveries took a major hit, and the consequences are still rippling across payers, providers, vendors, and regulators.

Why the 2023 RADV Rule Was Such a Big Deal

To understand the dispute, you have to start with how Medicare Advantage payment works. CMS pays Medicare Advantage organizations based in part on the documented health status of enrollees. Sicker patients generally mean higher risk scores, and higher risk scores generally mean higher payments. That is perfectly legitimate when diagnoses are accurate, clinically supported, and properly submitted. It becomes a very expensive mess when they are not.

RADV, short for Risk Adjustment Data Validation, is the mechanism CMS uses to check whether the diagnoses submitted for payment are backed up by medical records. In plain English, RADV asks a simple but financially explosive question: “Did the chart actually support what the plan told CMS?” If the answer is no, CMS can seek repayment.

The 2023 final rule supercharged that process in three major ways. First, it formally embraced extrapolation beginning with payment year 2018. That meant CMS could take findings from a sample of audited enrollees and project the payment error across the broader contract population. Second, CMS finalized a policy of not applying the fee-for-service, or FFS, adjuster in those audits. Third, CMS left itself room to use statistically valid sampling and extrapolation methods without locking one narrow methodology into the regulation.

That combination was not a routine tweak. It was the difference between a painful audit and a potentially balance-sheet-moving recovery. A few unsupported diagnoses in a small sample can sting. A statistically extrapolated recovery across a large Medicare Advantage contract can feel like someone dropped a piano on the quarterly forecast.

What the Fee-for-Service Adjuster Was Supposed to Do

The FFS adjuster sounds technical because it is technical, but the concept is not impossible. Historically, plans argued that medical documentation in traditional Medicare is not perfect either. So if CMS was comparing Medicare Advantage submissions against an imperfect fee-for-service benchmark, there should be some adjustment to account for documentation differences in the underlying system.

That was the core policy tension. CMS increasingly viewed unsupported diagnoses as a direct overpayment problem that should be corrected without softening the result through an FFS adjuster. Plans, meanwhile, argued that removing the adjuster distorted the comparison and created an uneven standard. In a world already crowded with actuarial terminology, this became the fight that would not leave the building.

Why Humana Challenged the Rule

Humana challenged the 2023 RADV final rule because the financial stakes were enormous and the legal footing, in its view, was shaky. The company argued that CMS had not simply polished an old proposal and moved on. Instead, it said the agency changed the logic of the rule in a way that did not give affected parties fair notice and a meaningful chance to comment.

That distinction is not academic. Under the Administrative Procedure Act, agencies generally cannot propose one thing, finalize another, and then act surprised when people complain. A final rule must be a logical outgrowth of what was proposed. That phrase sounds like something a law professor says right before assigning 200 pages of reading, but the principle is pretty intuitive: the public must be able to anticipate the agency’s final path well enough to comment intelligently.

In the RADV dispute, the court concluded that CMS had shifted the justifications for dropping the FFS adjuster in a way that failed that test. In the earlier proposal, the agency had pointed to different rationales. By the time the 2023 final rule arrived, the reasoning had changed in important ways, including new emphasis on statutory interpretation and the coding-intensity adjustment. The court said that was not a proper logical outgrowth of the proposal.

What the Court Actually Did

The court vacated and remanded the February 1, 2023 CMS final rule. That word, vacated, is the legal equivalent of yanking the rug out from under the rule. The court did not merely scold CMS or ask for a cleaner memo next time. It set the rule aside and sent the matter back to the agency.

Just as important, the court’s reasoning was procedural. It did not hold that extrapolation is always unlawful. It did not hold that CMS can never remove the FFS adjuster. It did not say the government must permanently abandon aggressive Medicare Advantage oversight. Instead, the ruling said CMS failed to follow the proper notice-and-comment path required by federal administrative law when it finalized this particular rule in this particular way.

That is why this case matters beyond RADV. It is a reminder that even when an agency may have a strong policy argument, procedure still matters. In health care regulation, procedure is not decoration. It is the plumbing. When the plumbing fails, the whole house gets weird fast.

Why the Decision Matters for Medicare Advantage Plans

For Medicare Advantage organizations, the vacatur created immediate uncertainty. If the 2023 final rule is off the books unless restored on appeal or reissued through a compliant rulemaking process, what exactly governs extrapolated recoveries for payment year 2018 and later? How should plans reserve for potential repayments? What assumptions should actuaries use? How much confidence should finance teams place in prior risk-adjustment strategies? And perhaps most urgently: should anyone exhale?

The answer to that last question is “only a little.” The decision gave plans breathing room, but not a permanent hall pass. CMS has been crystal clear that RADV oversight is not going into hibernation. The agency has continued to emphasize payment integrity, accelerate audits, expand the number of audited contracts, publish new timelines and Q&As, and initiate newer payment-year audits. In other words, the legal theory behind the 2023 final rule got walloped, but the government’s appetite for oversight did not.

That distinction matters because some people hear “rule vacated” and imagine an audit-free paradise with sunshine, birdsong, and no chart requests. That is not the world we are living in. The world we are living in still includes RADV, still includes record reviews, and still includes real financial exposure. It just includes more legal uncertainty around the exact framework CMS can use for certain extrapolated recoveries.

Why CMS Is Still Pressing Ahead

CMS’s persistence is not hard to understand. The agency’s own payment integrity numbers still show billions in Medicare Part C improper payments, largely tied to insufficient documentation supporting submitted diagnoses. OIG has also continued to spotlight diagnoses reported through health risk assessments and related chart reviews that generated billions in payments without corresponding service-record follow-up. MedPAC, meanwhile, continues to estimate that Medicare Advantage payments remain above what traditional Medicare would spend for similar beneficiaries.

Put simply, the government sees a lot of money on the table. When regulators see billions, they do not usually respond by taking up watercolor painting. They audit harder.

That is why CMS announced a broad expansion of RADV audits in 2025 and continued refining the program in 2026. Even with the final rule in litigation, the agency’s posture signals that plans should expect more scrutiny, tighter timelines, more operational expectations, and fewer chances to treat RADV as a slow-moving back-office nuisance.

What This Means for Providers and Vendors

Providers are not named parties in the court fight, but they are absolutely living in its shadow. When a health plan faces intensified RADV pressure, documentation requests tend to multiply. Provider groups may be asked for older records, cleaner diagnosis support, clarification on encounter details, or tighter coding hygiene. Vendors involved in chart retrieval, coding review, analytics, and risk adjustment operations also feel the heat because plans need faster, cleaner, and more defensible workflows.

That creates a familiar chain reaction. Compliance teams want supportable diagnoses only. Coding teams want documentation that passes review. Providers want fewer repetitive requests. Finance teams want certainty. Everyone wants the other department to answer emails faster. No one gets everything they want.

The Real Policy Fight Beneath the Lawsuit

Beneath the legal arguments, this case is really about two competing policy instincts. One says Medicare Advantage needs tougher oversight because unsupported diagnoses can drive overpayments, distort benchmarks, and weaken trust in the payment system. The other says oversight must be built on rules that are transparent, predictable, and lawfully issued, especially when the consequences can be massive.

Both instincts are understandable. Taxpayers should not be funding inflated payments built on unsupported diagnoses. At the same time, major enforcement frameworks cannot be assembled with procedural shortcuts and then defended with a shrug. The government does not get to say, “Yes, the process was messy, but we meant well.” Agencies have to show their work.

That is what makes this dispute more than a niche payer fight. It is a test case for how far CMS can push Medicare Advantage oversight, how carefully it must build the administrative record, and how courts will respond when regulators try to move fast in a program where the dollars are huge and the documentation fights are endless.

What Smart Organizations Should Be Doing Now

Even with the rule vacated, organizations should not treat this as a reason to relax documentation discipline. The better play is to assume scrutiny continues and prepare accordingly.

Plans should strengthen retrospective chart validation, sharpen deletion workflows for unsupported diagnoses, revisit contracts and vendor controls tied to chart review activities, and stress-test reserve assumptions under multiple litigation outcomes. Providers should focus on accurate, specific, clinically supported documentation rather than diagnosis inflation theater. Vendors should expect tougher quality standards and more requests for audit trails, version control, and proof that coding decisions were supportable.

The organizations most likely to weather the next phase well are the ones acting like the appeal could revive pieces of CMS’s strategy, a new rule could arrive later, and auditors are not going to suddenly become hobbyists.

Experiences From the Field: What This Battle Feels Like in Real Life

On paper, the case is about extrapolation, the FFS adjuster, notice-and-comment requirements, and the logical-outgrowth doctrine. In real life, it feels more like a tug-of-war between relief and dread.

For many Medicare Advantage plans, the first emotional reaction to the vacatur was obvious: relief. Finance leaders saw at least a temporary interruption to one of the industry’s most feared enforcement tools. Legal teams saw a strong procedural ruling they could point to. Executives who had been staring at potential extrapolated recoveries for payment years 2018 and later probably slept a little better that week. Not like babies, exactly. More like adults who set three alarms because they do not trust the universe.

But relief did not last long, because the operational machine never really stopped. Chart retrieval still had to happen. Coding accuracy still mattered. Internal audit committees still wanted updates. Actuaries still needed assumptions. Provider partners still needed guidance on documentation. And then CMS kept talking about expanding audits, accelerating the backlog, publishing fresh timelines, and moving forward with payment-year 2020 activity. That changed the mood from “maybe the storm passed” to “the storm changed shape.”

Provider organizations have their own version of the experience. Many are caught between wanting to support legitimate risk adjustment and not wanting to become unpaid archivists for a payer’s compliance emergency. Medical groups often experience RADV pressure as a flood of record requests, clarification questions, coding education sessions, and retrospective second-guessing. The legal case may be happening in appellate briefs, but the practical version shows up as someone asking for a chart from years ago by Friday afternoon.

Compliance and coding teams probably have the most complicated emotional landscape of all. They know accurate diagnosis capture matters. They also know overreach is dangerous. So they end up living in the narrow middle lane: pushing for documentation that is complete, clinically grounded, and defensible, while resisting the temptation to treat every suspect diagnosis as free revenue. In that environment, the vacatur is not a permission slip. It is a warning label.

Even investors and corporate strategists feel the effect. A rule like this touches reserves, earnings expectations, regulatory risk disclosures, acquisition assumptions, and long-term bid strategy. When the legal framework wobbles, it creates a strange combination of uncertainty and urgency. Nobody wants to overreact, but nobody wants to be the last person in the room to realize the risk model changed.

That is why the most realistic experience related to this topic is not celebration or panic. It is disciplined ambiguity. Organizations are being forced to operate in a world where the government remains aggressive, the courts remain relevant, and the final shape of RADV enforcement is still being written. That is not comfortable. But it is very familiar to anyone who has spent time in regulated health care.

Conclusion

The headline phrase “Fifth Circuit Vacates CMS Medicare Advantage 2023 RADV” captures the search intent, but the deeper story is even more interesting. The 2023 RADV final rule was built to strengthen CMS’s ability to recover Medicare Advantage overpayments through extrapolation and without an FFS adjuster. A federal court vacated that rule on procedural grounds, and the fight is now bound up with the Fifth Circuit. That does not mean RADV is dead. It means the rules governing one of CMS’s most important payment integrity tools are in flux.

For Medicare Advantage plans, providers, vendors, and compliance teams, the practical takeaway is simple: keep documentation clean, keep audit processes tight, and do not confuse legal turbulence with regulatory surrender. CMS still wants tougher oversight, courts still want lawful rulemaking, and the industry still has to live in the space between those two demands. In health care policy, that space is rarely quiet. It is just where the real story happens.